Skip to main content

Table 4 Association between lung function decline and development of CPA (n = 1842)

From: Mortality and lung function decline in patients who develop chronic pulmonary aspergillosis after lung cancer surgery

Models

FVC decline (mL/year)

for CPA (+) (vs. CPA (–))

FEV1 decline (mL/year)

for CPA (+) (vs. CPA (–))

β coefficient

95% CI

p

β coefficient

95% CI

p

Crude

− 132.5

− 206.0 to − 58.9

< 0.001

− 49.1

− 105.6 to 7.4

0.088

Model 1

− 143.8

− 217.1 to − 70.4

< 0.001

− 55.1

− 111.1 to 0.9

0.054

Model 2

− 97.3

− 172.8 to − 21.7

0.012

− 16.9

− 74.4 to 40.6

0.564

Model 3

− 129.8

− 204.6 to − 55.0

0.001

− 40.2

− 97.1 to 16.6

0.165

Model 4

− 93.0

− 168.9 to − 17.1

0.016

− 20.3

− 78.8 to 38.1

0.495

Model 5

− 103.6

− 179.2 to − 27.9

0.007

− 14.4

− 72.1 to 43.4

0.626

  1. Model 1 was adjusted for baseline lung function; FVC [L] at baseline for FVC decline; FEV1 [L] at baseline for FEV1 decline
  2. Model 2 was adjusted for selected variables with p value < 0.20 in univariate analysis: sex, BMI, smoking status, COPD/Asthma, interstitial lung disease, baseline FVC [L], tumor histology, surgical approach (VATS or thoracotomy), type of surgical resection, adjuvant treatment (none, chemotherapy only, radiotherapy only, chemotherapy and radiotherapy both), and bronchodilator use for FVC decline; sex, BMI, smoking status, COPD/Asthma, baseline FEV1 [L], tumor histology, surgical approach (VATS or thoracotomy), types of surgical resection, and adjuvant treatment (none, chemotherapy only, radiotherapy only, chemotherapy and radiotherapy both) for FEV1 decline
  3. Model 3 was adjusted for variables that were generally considered to influence the decline of lung function: age, sex, BMI, smoking status, COPD/Asthma, interstitial lung disease, baseline FVC [L] or FEV1 [L], and bronchodilator use
  4. Model 4 was adjusted for variables related to lung cancer treatment and variables considered to be related to the development of CPA: BMI, smoking status, interstitial lung disease, tumor histology, surgical approach (VATS or thoracotomy), types of surgical resection, postoperative pulmonary complications within 30 days, and adjuvant treatment: none, chemotherapy only, radiotherapy only, chemotherapy and radiotherapy both)
  5. Model 5 was adjusted for all the preceding variables: age, sex, BMI, smoking status, history of pulmonary tuberculosis, COPD/Asthma, interstitial lung disease, baseline FVC [L] or FEV1 [L], tumor histology, surgical approach (VATS or thoracotomy), types of surgical resection, postoperative pulmonary complications, adjuvant treatment (none, chemotherapy only, radiotherapy only, chemotherapy and radiotherapy both), and bronchodilator use
  6. There were no missing data, so no patients were excluded from the multivariate analysis of the five models
  7. CPA Chronic pulmonary aspergillosis, FVC Forced vital capacity, FEV1, Forced expiratory volume in one second, CI Confidence interval, BMI Body mass index, COPD Chronic obstructive pulmonary disease, VATS Video-assisted thoracoscopic surgery
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us